within Pharmacolibrary.Drugs.R_RespiratorySystem.R05C_ExpectorantsExclCombinationsWithCoughSuppressant.R05CB15_Erdosteine;

model Erdosteine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 3.222222222222222e-06,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.00032,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007166666666666667,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Erdosteine</td></tr><tr><td>ATC code:</td><td>R05CB15</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.32</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Erdosteine is a mucolytic agent that is used primarily for the treatment of chronic obstructive pulmonary disease (COPD) and chronic bronchitis. It acts by breaking down mucus structure, making it easier to expectorate. Approved and in use in several countries for respiratory conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of erdosteine administered orally in healthy adult volunteers.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R05CB15 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Erdosteine;
